We partnered with the Muscular Dystrophy Association (MDA) and a top-five pharma sponsor to engage and educate both specialist and generalist clinicians around Duchenne muscular dystrophy (DMD).
Together with the expertise of the MDA and its members, we developed an educational program designed to reduce time to diagnosis and accelerate early DMD specialist referral.
Target audience: Global scope with a focus on neurologists, pediatricians, and primary care physicians in the US
A focused educational series aligned to key learning objectives, featuring:
A highly active community of specialists and generalists with an interest in neuromuscular conditions developed on MedShr, with >6,500 highly engaged members of MDA-linked discussion groups
>84,605 Unique HCPs reached
The program supported a multidisciplinary approach to treatment, including discussion of gene therapy and how this is different from conventional drug therapy